HomeCompareVEII vs JNJ

VEII vs JNJ: Dividend Comparison 2026

VEII yields 400000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VEII wins by $5.011119029548644e+32M in total portfolio value
10 years
VEII
VEII
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full VEII calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — VEII vs JNJ

📍 VEII pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVEIIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VEII + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VEII pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VEII
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, VEII beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VEII + JNJ for your $10,000?

VEII: 50%JNJ: 50%
100% JNJ50/50100% VEII
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VEII
No analyst data
Altman Z
-2.7
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VEII buys
0
JNJ buys
0
No recent congressional trades found for VEII or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVEIIJNJ
Forward yield400000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$5.011119029548644e+32M$30.3K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$5.010957816668433e+32M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VEII vs JNJ ($10,000, DRIP)

YearVEII PortfolioVEII Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$40,010,700$40,000,000.00$10,592$272.30+$40.00MVEII
2$149,615,521,729$149,572,710,280.37$11,289$357.73+$149615.51MVEII
3$522,880,052,725,200$522,719,964,116,949.25$12,123$472.89+$522880052.71MVEII
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$13,141$629.86+$1707862989289.03MVEII
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$14,408$846.81+$5213509402845684.00MVEII
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$16,021$1,151.60+$14874219058409543680.00MVEII
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$18,122$1,588.22+$3.966119623405075e+22MVEII
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$20,930$2,228.20+$9.88384363503273e+25MVEII
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$24,792$3,191.91+$2.302052364743449e+29MVEII
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$30,274$4,689.40+$5.011119029548644e+32MVEII

VEII vs JNJ: Complete Analysis 2026

VEIIStock

Value Exchange International, Inc. provides customer-centric technology solutions to the retail industries in the People's Republic of China, Hong Kong, Malaysia, and the Philippines. The company offers credit and debit card processing services to multinational retailers. It also provides systems maintenance and related services, including software patches and software code revisions; installing, testing, and implementing of software; training of customer personnel for the use of software; and technical support for software systems. In addition, the company offers system installation and implementation services comprising project planning, system analysis and design, hardware and consumables selection advice and sales, and system hardware maintenance services; and systems development and integration services. Further, it engages in the software development; trading and servicing of computer hardware and software; IT service call-center activities; and marketing, sale, and maintenance of point of sale (POS) software under the edgePOS brand, as well as sale of third party POS software programs. The company was formerly known as Sino Payments, Inc. and changed its name to Value Exchange International, Inc. in December 2017. Value Exchange International, Inc. was incorporated in 2007 and is based in Sha Tin, Hong Kong.

Full VEII Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VEII vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VEII vs SCHDVEII vs JEPIVEII vs OVEII vs KOVEII vs MAINVEII vs ABBVVEII vs MRKVEII vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.